4-[(1-Pyrrolidinylsulfonyl)methyl]aniline CAS 334981-10-1 Purity >99.0% (HPLC) Almotriptan Aniline Precursor Factory

Short Description:

Name: 4-[(1-Pyrrolidinylsulfonyl)methyl]aniline

CAS: 334981-10-1

Purity: >99.0% (HPLC)

Appearance: White to Faint Yellow Crystalline Powder

Intermediate of Almotriptan Malate (CAS: 181183-52-8)

High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

Description:

Chemical Properties:

Chemical Name 4-[(1-Pyrrolidinylsulfonyl)methyl]aniline
Synonyms 1-[(4-Aminobenzyl)sulfonyl]pyrrolidine; Almotriptan Aniline Precursor
CAS Number 334981-10-1
CAT Number RF-PI1948
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C11H16N2O2S
Molecular Weight 240.32  
Melting Point 170.0 to 176.0℃
Density 1.31
Solubility Slightly Soluble in Toluene
Brand Ruifu Chemical

Specifications:

Item Specifications
Appearance White to Faint Yellow Crystalline Powder
Purity / Analysis Method >99.0% (HPLC) 
Loss on Drying <0.50%
Residue on Ignition <0.50%
Max Single Impurity <0.50%
Total Impurities <1.00%
Heavy Metals <20ppm
Infrared Spectrum Conforms to Structure
NMR  Conforms to Structure
Test Standard Enterprise Standard
Usage Almotriptan Aniline Precursor

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture

Advantages:

1

FAQ:

Application:

4-[(1-Pyrrolidinylsulfonyl)methyl]aniline (CAS: 334981-10-1) is an intermediate in the preparation of Almotriptan Malate (CAS: 181183-52-8), Almotriptan Aniline Precursor. Almotriptan Malate is a kind of triptan drug which can be used for the treatment of migraine headaches. Almotriptan is belong to a drug category of selective serotonin receptor agonists. Almotriptan has a high and specificity affinity for serotonin 5-HT receptors, further leading to vascoconstriction of the brain blood vessel and affecting the redistribution of blood flow. These effects stop pain signals from being sent to the brain, and further suppressing the release of certain natural substances which cause pain, nausea and other migraine symptoms. However, Almotriptan doesn’t prevent migraine attacks. Almotriptan, marketed in 2000, has the highest oralbioavailability among all triptans. Almotriptan is metabolizedby both MAO-A and CYP3A4, thus has a more favorableside effects profile when compared with Sumatriptan.

  • Write your message here and send it to us